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Complete and accurate registration of cancer is needed to provide reliable data on cancer incidence and to investigate
aetiology. Such data can be derived from national cancer registries, but also from large population-based cohort studies. Yet,
the concordance and discordance between these two data sources remain unknown. We evaluated completeness and accuracy
of cancer registration by studying the concordance between the population-based Rotterdam Study (RS) and the Netherlands
Cancer Registry (NCR) between 1989 and 2012 using the independent case ascertainment method. We compared all incident
cancers in participants of the RS (aged ≥45 years) to registered cancers in the NCR in the same persons based on the date of
diagnosis and the International Classiﬁcation of Diseases (ICD) code. In total, 2,977 unique incident cancers among 2,685
persons were registered. Two hundred eighty-eight cancers (9.7%) were coded by the RS that were not present in the NCR.
These were mostly nonpathology-conﬁrmed lung and haematological cancers. Furthermore, 116 cancers were coded by the
NCR, but not by the RS (3.9%), of which 20.7% were breast cancers. Regarding pathology-conﬁrmed cancer diagnoses,
completeness was >95% in both registries. Eighty per cent of the cancers registered in both registries were coded with the
same date of diagnosis and ICD code. Of the remaining cancers, 344 (14.5%) were misclassiﬁed with regard to date of
diagnosis and 72 (3.0%) with regard to ICD code. Our ﬁndings indicate that multiple sources on cancer are complementary and
should be combined to ensure reliable data on cancer incidence.
Introduction
With an estimated number of 3.9 million new diagnoses and
1.9 million deaths from cancer in Europe in 2018, cancer poses
a huge burden on societies.1 Optimal cancer registration is not
only crucial to provide reliable estimations of incidence and
mortality,2 but is also pivotal to better understand risk factors
of cancer.3 Extensive quality checks are performed before can-
cer registry data are accepted in Cancer Incidence in Five Con-
tinents, the reference source of data on international cancer
incidence.4 However, the number of validation studies of can-
cer registries is limited.
Methods to assess completeness and accuracy of cancer regis-
tries can be classiﬁed into two categories, that is, qualitative and
quantitative methods.5 Qualitative methods include comparison
of the performance of a cancer registry with other registries,
such as comparison with historical data or other populations. In
contrast to qualitative methods, quantitative methods including
independent case ascertainment, ﬂow method, or capture-
recapture methods provide a numerical evaluation of the extent
to which all eligible events are registered and are therefore more
appealing.
Several studies have compared cancer registries in Europe
using quantitative methods.6–17 In the Netherlands, the Neth-
erlands Cancer Registry (NCR) managed by the Netherlands
Comprehensive Cancer Organisation (IKNL) registers cancers
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nationwide and provides information regarding cancer inci-
dence, prevalence, risk, mortality and survival of cancer.18
Completeness of registration by the NCR has been estimated
at 98.7% in 1990 based on cancers registered by general prac-
titioners.6 A second evaluation in 1993 showed completeness
of 96.2%.7 However, the potential added value of a large pro-
spective population-based cohort study to the completeness
and accuracy of cancer registration by the national cancer reg-
istry has not been evaluated.
Therefore, in our study, we investigated the concordance
of cancer registration by the NCR with a large population-
based cohort study, the Rotterdam Study (RS).
Materials and Methods
Setting
Our study is embedded within the RS, an ongoing population-
based cohort study in Rotterdam, the Netherlands, designed to
study the occurrence and determinants of age-related diseases.
Besides cancer, the RS focuses on the aetiology, prediction and
prognosis of cardiovascular, endocrine, hepatic, neurological,
ophthalmologic, psychiatric, dermatological, otolaryngologic,
locomotor and respiratory diseases. The RS started in 1990 with
7,983 participants (response of 78%) aged ≥55 years and resid-
ing in the district Ommoord, a suburb of Rotterdam. This ﬁrst
subcohort (RS-I) was extended with a second subcohort (RS-II)
in 2000, consisting of 3,011 participants (response of 67%) and
with a third subcohort (RS-III) in 2006, composed of 3,932 par-
ticipants aged ≥45 years (response of 65%). The design of the
RS has been described in detail.19 In total, the RS comprises
14,926 participants aged ≥45 years at study entry.
The RS has been approved by the Medical Ethics Committee
of Erasmus Medical Center and by the board of The Netherlands
Ministry of Health, Welfare and Sports. A written informed con-
sent was obtained from all participants.
Assessment of cancer
The Rotterdam Study. Diagnosis of incident cancer is based
on medical records of general practitioners (including hospital
discharge letters) and furthermore through linkage with the
national hospital discharge registry (Landelijke Medische Regis-
tratie [LMR]) hosted by Dutch Hospital Data and histology and
cytopathology registries in the region (part of the nationwide
network PALGA). Cancer diagnosis is coded independently by
two physicians and classiﬁed according to the International
Classiﬁcation of Diseases, 10th revision (ICD-10). In case of dis-
crepancy between sources, consensus is sought through consul-
tation with a physician specialised in internal medicine. Date of
diagnosis is based on the pathology date, or—if unavailable—
date of hospital admission or hospital discharge letter. Level of
uncertainty of diagnosis is established as certain (pathology-con-
ﬁrmed), probable (e.g., based on imaging features or elevated
tumour markers without pathological conﬁrmation) and possi-
ble (e.g., based on symptoms and physical examination or suspi-
cion based on imaging features or elevated tumour markers
without pathological conﬁrmation). Possible cancers were not
included in the current study. Registration of cancer diagnoses
is completed up to January 1, 2013.
The Netherlands Cancer Registry. The NCR is a population-
based cancer registry with nationwide coverage since 1989. Can-
cer diagnoses are notiﬁed by the nationwide network and
registry of histology and cytopathology (PALGA) and in addi-
tion through linkage with the LMR hosted by Dutch Hospital
Data. Each cancer is coded by trained registration clerks (inter-
nal education of 1 year) according to the International Classiﬁ-
cation of Diseases for Oncology, 3rd edition (ICD-O-3) based
on information gathered from medical ﬁles at the hospital. Date
of diagnosis is coded according to international coding rules and
mostly based on the date of ﬁrst pathological conﬁrmation,
or—if unavailable—date of ﬁrst hospital admission. In addition,
information about tumour histology, tumour stage and primary
treatment was retrieved.
Linkage
All persons from the RS (n = 14,926) were linked with patients
in the NCR based on the following characteristics: date of birth,
sex, birth name, initials, zip code and—if applicable—date of
death. If a participant had multiple zip codes due to moving,
historical zip codes were also included. All data were pseudo-
nymised using a double-pass procedure beforehand. Data
exchange took place between secured encrypted data servers. All
cancers diagnosed between 1989 and 2012 were included. To
make an equal comparison between the two cancer registries, we
excluded the following cancers: cancers diagnosed before entry
in the RS or after January 1, 2013, cancers solely coded as cause
of death, skin cancers (due to different registration methods),
benign or borderline tumours and carcinomas in situ other than
ductal carcinoma in situ of the breast (Fig. 1). If a cancer was
What’s new?
While national cancer registries and population-based cohort studies are the primary sources of data on cancer risk and
incidence, the degree to which these data sets are concordant remains unknown. In this investigation, the authors evaluated
concordance between the population-based Rotterdam Study and the Netherlands Cancer Registry. The two data sets were
highly concordant for pathology-conﬁrmed cancers and cancer site. Non-pathology-conﬁrmed cancers, however, were under-
registered in the Netherlands Cancer Registry, potentially resulting in underestimation of cancer incidence. The ﬁndings
highlight the important role that different sources of cancer diagnosis registration serve in providing reliable estimates of
cancer incidence.
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only coded by the RS or the NCR (unmatched cancers), we per-
formed a second linkage with previously excluded cancers (that
is for instance, date of diagnosis prior to study entry or cancer
solely registered as cause of death). In case of multiple cancers
per patient, we included all different cancers.
We were interested in (i) the completeness and (ii) the
accuracy of both registries. Since we do not know the true
number of cancers in the study population, we deﬁned com-
pleteness as the proportion of cancers in one registry in rela-
tion to the total number of cancers coded by at least one of
the registries. Completeness was determined for pathology-
conﬁrmed diagnoses of cancer and nonpathology-conﬁrmed
diagnoses separately, as well as for all cancers combined.
Accuracy of the date of cancer diagnosis and ICD code
was investigated for cancers that were present in both regis-
tries (matched cancers). We digitally converted the ICD-O-3
codes into ICD-10 codes. These matched cancers were classi-
ﬁed into the following categories: matched date of diagnosis
(difference in date of diagnosis of 1 month or less) and ICD
code, misclassiﬁcation of date of diagnosis (two categories: dif-
ference in date of diagnosis of more than 1 month but less
than 1 year and difference of more than 1 year), or mis-
classiﬁcation of ICD code (different ICD code and different
organ system). An overview of the different ICD-10 codes
used for the categorisation into different organ systems is
presented in Supporting Information Table S1.
Cancers in Rotterdam Study
(n = 6,162)
Excluded:
• Date of diagnosis before study entry (n = 840)
• Date of diagnosis after January 1st, 2013 
(n = 735)
• Skin cancer (n = 640)
• Carcinoma in situ except DCIS (n = 149)
• Benign/borderline tumours (n = 73) 
Included cancers (n = 2,806)
Cancers in Netherlands 
Cancer Registry (n = 4,984)
Included cancers (n = 2,547)
Excluded:
• Date of diagnosis before study entry (n = 1,057)
• Cancer as cause of deatha (n = 136)
• Skin cancer (n = 2,163)
Linkage of cancers
Matched cancers (n = 2,376)b Unmatched cancers (n = 601)
• Only in Rotterdam Study (n = 430)
• Only in Netherlands Cancer registry (n = 171)
• Only in Rotterdam Study (n = 288)
• Only in Netherlands Cancer registry (n = 116)
Second linkage with excluded cancersc
• Date of diagnosis before study entry (n = 12)
• Cancer as cause of deatha (n = 29)
• Misclassification of skin cancer (n = 18)
• Misclassification of carcinoma in situ (n = 119)
• Misclassification of benign tumour (n = 19)
Rotterdam Study
(n = 14,926)
Linkage of participants 
Rotterdam Study
Netherlands Cancer Registry
• Matched date and ICD code (n = 1,965)
• Misclassification date >1 month and <1 year (n = 324)
• Misclassification date >1 year (n = 20)
• Misclassification ICD code (n = 72)
Figure 1. Flowchart of matched and unmatched cancers after linkage between the Rotterdam Study and Netherlands Cancer Registry.
Abbreviations: DCIS, ductal carcinoma in situ; ICD, International Classiﬁcation of Diseases. aCancer as cause of death corresponds to cancer
solely coded as cause of death, without a date of incident cancer diagnosis. bFive cancers were both misclassiﬁed with regard to date
>1 month and <1 year and with regard to ICD code. Therefore, the number of matched cancers is lower than the total number of cancers in the
different misclassiﬁcation categories. cA second linkage was performed to preclude whether unmatched cancers were present in both
databases, but were excluded prior to the linkage of cancers based on the exclusion criteria.
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Unmatched cancers only coded by the RS and cancers mis-
classiﬁed with regard to the date of diagnosis or ICD code
were reassessed through evaluation of the patient’s original
medical ﬁles collected by the RS.
Statistical analyses
Differences in patient characteristics were evaluated using an
independent t-test (continuous variables) or a chi-squared test
(categorical variables). Two-sided p < 0.05 was considered statis-
tically signiﬁcant. Statistical analyses were performed using SPSS
and the ‘UpSetR’ package from R software Version 3.3.2.20
Data availability
Data can be obtained upon request. Requests should be
directed toward the management team of the Rotterdam
Study (secretariat.epi@erasmusmc.nl), which has a protocol
for approving data requests. Because of restrictions based on
privacy regulations and informed consent of the participants,
data cannot be made freely available in a public repository.
The Rotterdam Study has been approved by the Medical
Ethics Committee of the Erasmus MC (registration number
MEC 02.1015) and by the Dutch Ministry of Health, Welfare
and Sport (Population Screening Act WBO, license number
1071272-159521-PG). The Rotterdam Study has been entered
into the Netherlands National Trial Register (NTR; www.
trialregister.nl) and into the WHO International Clinical Tri-
als Registry Platform (ICTRP; www.who.int/ictrp/network/
primary/en/) under shared catalogue number NTR6831.
Results
In the same source population, based on 14,926 participants of
the RS, 2,806 incident cancers among 2,579 persons were coded
by the RS and 2,547 cancers among 2,342 persons were coded
by the NCR (Fig. 1). Linkage of the two registries resulted in a
total of 2,977 unique cancers among 2,685 persons.
Completeness of registries
After the ﬁrst linkage, 2,376 cancers among 2,227 persons were
coded by both registries. The remaining 601 unmatched can-
cers were coded solely by one of the two registries, of which
197 cancers could eventually be matched after a second linkage
with previously excluded cancers. This resulted in 288 cancers
(9.7%) among 284 persons coded solely by the RS, of which
105 cancers (36.5%) were pathology-conﬁrmed. Furthermore,
116 cancers (3.9%) among 115 persons were coded solely by
the NCR, of which 109 cancers (94.0%) were pathology-
conﬁrmed. Taking only cancers after the second linkage into
account, the RS had a completeness of 95.8% (2,664 out of
2,780 cancers) and the NCR of 89.6% (2,492 out of 2,780 can-
cers) of all cancers. Regarding pathology-conﬁrmed cancers
(2,475 cancers), completeness was 95.3% in the RS and 95.2%
in the NCR. Completeness of nonpathology-conﬁrmed cancers
(305 cancers) was 97.7% in the RS and 40.0% in the NCR.
Persons with matched cancer diagnoses were signiﬁcantly
younger at baseline and at ﬁrst cancer diagnosis than those
coded solely by the RS (p < 0.001 and p < 0.001, respectively)
or by the NCR (p < 0.001 and p < 0.001, respectively, Table 1).
Table 1. Characteristics of persons with matched and unmatched cancers in the Rotterdam Study and the Netherlands Cancer Registry
Persons with unmatched cancers (n = 397)
Characteristic
Persons with matched
cancers (n = 2,227)
Rotterdam study
(n = 284)
Netherlands Cancer
Registry (n = 115)
Age at study entry, years, median (IQR) 65.1 (11.5) 71.5 (13.0) 69.0 (11.8)
Sex, women, n (%) 1,081 (48.5) 151 (53.2) 61 (53.0)
Education, n (%)1
Primary 395 (17.7) 69 (24.3) 22 (19.1)
Lower 897 (40.3) 104 (36.6) 43 (37.4)
Further 647 (29.1) 89 (31.3) 33 (28.7)
Higher 261 (11.7) 19 (6.9) 15 (13.0)
Age at first cancer diagnosis, years, n (%)
45–65 355 (15.9) 16 (5.6) 10 (8.7)
65–75 856 (38.4) 50 (17.6) 27 (23.5)
75–85 794 (35.7) 126 (44.4) 51 (44.3)
>85 222 (10.0) 92 (32.4) 27 (23.4)
Mean (SD) 74.0 (8.5) 80.5 (8.6) 78.2 (9.1)
Persons in Rotterdam Study or Netherlands Cancer Registry do not sum up to total number of persons with unmatched cancers since some persons with
unmatched cancers overlap. Numbers of education are shown without imputation and therefore do not sum up to 100%.
1Education levels were assessed during home interviews according to the following categories: primary: primary education, lower: lower/intermediate
general education/lower vocational education, intermediate: intermediate vocational education/higher general education or higher: higher vocational
education/university.
Abbreviations: IQR, interquartile range; SD, standard deviation.
4 Cancer ascertainment in longitudinal research
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Cancer sites that were most frequently registered by both reg-
istries were gastric and oesophagus (93.4% of all these cancers
were included in both registries), head and neck (91.0%) and male
genital organs (90.0%, Table 2). Lung and mesothelioma was the
most common cancer site among cancers coded solely by the RS
(20.5% of all cancer cases solely coded by the RS). Haematological
cancer represented the second most frequent diagnosis that was
coded solely by the RS (16.0%), of which chronic lymphocytic
leukaemia was the most common diagnosis (39.1%). The distribu-
tion of different cancer sites among cancers coded solely by the
Table 2. Overview of cancer sites according to matched and unmatched cancers
Unmatched cancers (n = 404)
Cancer site
Matched cancers
(n = 2,376)
Rotterdam Study
(n = 288)
Netherlands Cancer
Registry (n = 116)
Head and neck 71 (91.0) 4 (5.1) 3 (3.8)
Oesophagus and gastric 141 (93.4) 5 (3.3) 5 (3.3)
Colorectal 393 (89.1) 30 (6.8) 18 (4.1)
Hepato-Pancreato-Biliary 121 (81.2) 26 (17.4) 2 (1.3)
Lung and mesothelioma 351 (82.4) 59 (13.8) 16 (3.8)
Bone and soft tissue 15 (71.4) 2 (9.5) 4 (19.0)
Breast 366 (89.5) 19 (4.6) 24 (5.9)
Female genital organs 101 (87.8) 10 (8.7) 4 (3.5)
Male genital organs 380 (90.0) 27 (6.4) 15 (3.6)
Unitary tract 176 (80.7) 28 (12.8) 14 (6.4)
Central nervous system 19 (73.1) 7 (26.9) 0
Haematological 165 (76.7) 46 (21.4) 4 (1.9)
Other 21 (67.7) 4 (12.9) 6 (19.4)
Unknown primary origin 56 (71.8) 21 (26.9) 1 (1.3)
Numbers are displayed in the total number of cancer site (percentage per row).
Table 3. Overview of cancer sites according to correctly classified and misclassified cancers
Misclassiﬁed cancers (n = 411)1
Cancer site
Correctly classiﬁed
cancers (n = 1,965)
Date of diagnosis
(n = 344)
ICD code
(n = 72)
More than 1 month
(n = 324)2
More than 1 year
(n = 20)
Head and neck 52 (73.2) 19 (26.8) 0 0
Oesophagus and gastric 124 (87.9) 13 (9.2) 0 4 (2.8)
Colorectal 361 (91.9) 25 (6.4) 1 (0.3) 6 (1.5)
Hepato-Pancreato-Biliary 88 (72.1) 24 (19.7) 1 (0.8) 9 (7.4)
Lung and mesothelioma 291 (82.2) 41 (11.6) 2 (0.6) 20 (5.6)
Bone and soft tissue 10 (66.7) 5 (33.3) 0 0
Breast 323 (88.3) 37 (10.1) 2 (0.5) 4 (1.1)
Female genital organs 89 (88.1) 9 (8.9) 1 (1.0) 2 (2.0)
Male genital organs 296 (77.9) 79 (20.9) 5 (1.3) 0
Unitary tract 136 (76.8) 38 (21.5) 0 3 (1.7)
Central nervous system 15 (78.9) 3 (15.8) 0 1 (5.3)
Haematological 130 (78.8) 27 (16.4) 8 (4.8) 0
Other 10 (47.6) 1 (4.8) 0 10 (47.6)
Unknown primary origin 40 (71.4) 3 (5.4) 0 13 (23.2)
Numbers are displayed in total number per cancer site (percentage per row). Cancers misclassified with regard to ICD code are classified according to
the different cancer groups based on the ICD code of the Rotterdam Study.
1Five cancers were both misclassified with regard to date >1 month and <1 year and with regard to ICD code. Therefore, the number of misclassified can-
cers is lower than the total number of cancers in the different misclassification categories.
2Difference in date of diagnosis more than 1 month and less than 1 year.
Abbreviation: ICD, International Classification of Diseases.
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NCR was comparable to the distribution among the matched can-
cers, with breast as the most frequently diagnosed cancer site
(20.7%). One-third of all cancers solely coded by the NCR were
second primary cancers of the same cancer site, with the highest
numbers for breast (75.0%) and colon cancers (56.3%).
Accuracy of registries
One thousand nine hundred sixty-ﬁve cancers out of 2,376
matched cancers (82.7%) were coded with the same date of
diagnosis and ICD code by both registries. Most frequent cor-
rectly classiﬁed cancer sites were colorectal (91.9% of all colo-
rectal cancers), breast (88.3%) and oesophagus and gastric
(87.9%). The remaining cancers were misclassiﬁed with regard
to the date of diagnosis (344 cancers [14.5%]) or ICD code
(72 cancers [3.0%]).
Misclassiﬁcation of date was further divided into a differ-
ence in date of diagnosis more than 1 month and less than
1 year (324 cancers), and more than 1 year (20 cancers,
Table 3). Male genital cancer with prostate cancer as most fre-
quent cancer was the most common cancer site among can-
cers with a difference in date of diagnosis of more than
1 month (24.4%) and the second among cancers misclassiﬁed
for more than 1 year (25.0%), after haematological malignan-
cies (40.0%). Date of diagnosis was more often accurately reg-
istered by the NCR than by the RS based on evaluation of the
original medical ﬁles (Supporting Information Table S2).
Misclassiﬁcation regarding ICD code was less common, with
72 cancers (3.0%) classiﬁed as misclassiﬁcation of ICD code and
organ system (Supporting Information Fig. S1). Most differences
in ICD code were found for lung cancers or cancers coded as
tumour of unknown primary origin (Supporting Information
Fig. S1).
Discussion
In our study, we investigated the concordance of cancers in a
prospective population-based cohort study, the RS, with the
NCR. There was a high concordance with regard to pathology-
conﬁrmed cancers (>95%), but the RS registered a higher num-
ber of nonpathology-conﬁrmed cancers. Furthermore, there was
a high accuracy with regarding cancer site, but the accuracy with
regard to the date of diagnosis was lower in the RS than in the
NCR. These ﬁndings can help to identify the reasons for inaccu-
rate cancer registration and emphasise that cancer registration
by national cancer registries may complement population-based
cohort studies and vice versa.
Completeness varying between 90 and 100% is considered as
acceptable to estimate optimal cancer incidence, provided that
there are no large differences regarding cancer site or age at can-
cer diagnosis between registered and unregistered cancers.3
Completeness of pathology-conﬁrmed cancers was comparable
between the RS and the NCR, but we found that the number of
nonpathology-conﬁrmed cancers, with lung and haematological
cancers, in particular, were underreported in the NCR. This can
be explained by the use of different sources of cancer
registration, with the RS having access to the medical records
of general practitioners in addition to notiﬁcation of cancer
diagnoses through the pathology database. Regarding the can-
cers missed by the RS, we observed that one-third of these
cancers were second primary cancers. It is often not well
documented in discharge letters whether a second tumour is a
recurrent cancer, metastasis or second primary cancer, in
contrast to the documentation in medical ﬁles in hospitals to
which the NCR has access. Although under-registration of
second primary cancers within the same organ will not affect
cancer statistics, because these cancers are not included in
cancer incidence and survival estimations,21 it may impact
aetiological research questions.
Furthermore, we found that cancers coded by solely one reg-
istry occurred often in older persons, which has been observed
in previous studies as well.2,6,22 This observation can be
explained because, compared to younger patients, pathological
conﬁrmation through biopsies can be limited in elderly patients
due to poor clinical condition and prognosis.23–25 Harms caused
by histological tissue acquisition for pathological conﬁrmation
without consequences for cancer treatment may outweigh the
beneﬁt of knowing the diagnosis in these patients. Furthermore,
older patients are less often referred to the hospital and are more
likely to be treated (in nursing homes) by their general practi-
tioner.26 Such cancers will remain unnoticed in the NCR,
because there is no linkage with general practitioners.
Although the RS had a higher degree of completeness of
nonpathology-conﬁrmed cancers, the accuracy of calendar date
of cancer diagnosis was lower compared to the NCR. The RS
aims to register the date of cancer diagnosis based on the date of
biopsy (solid cancers) or laboratory assessment (haematological
cancers). However, this information is not always documented
in the hospital discharge letters and other medical ﬁles obtained
from general practitioners. If the date of pathological conﬁrma-
tion is unavailable, a proxy is taken based on the date of hospital
admission or the date of the medical letter. Most discrepancies
regarding date of diagnosis were found for male genital organ
cancer, mostly represented by prostate cancer, and
haematological cancer. Prostate cancer is frequently detected by
elevated prostate-speciﬁc antigen (PSA) levels. Since the long-
term beneﬁt of invasive treatment for prostate cancer is
questionable,27 treatment options such as watchful waiting and
active surveillance are often applied for indolent localised pros-
tate cancer. Monitoring of patients by measuring PSA levels
limits the need for pathological conﬁrmation of the cancer in
contrast to cancer at other sites. Pathology can be obtained in
case of cancer progression, which may occur months after the
initial clinical diagnosis. The dates across these different clinical
stages are not always accurately documented in medical letters,
resulting in misclassiﬁcation of the date of ﬁrst diagnosis. Differ-
ences in the date of diagnosis of haematological cancers were
explained by the different diagnostic examinations on which the
date of diagnosis was based (peripheral blood vs. bone marrow
biopsy).
6 Cancer ascertainment in longitudinal research
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In addition, we showed that few of the registered cancers
were misclassiﬁed with regard to ICD code. We considered
cancers with a different ICD code within the same organ sys-
tem as correctly classiﬁed, because part of the misclassiﬁcation
is due to different coding rules. These different coding rules
also explain the misclassiﬁed cancers with the ICD code for
‘tumour of primary origin’, with the RS being more lenient in
coding cancers according to the most probably primary origin.
Moreover, cancer diagnoses in the RS are coded indepen-
dently by two physicians, whereas cancers in the NCR are
coded by one trained registration clerk, which could affect the
accuracy of registered cancers as well.28
The main strength of our study is the independent case
ascertainment method used to study the concordance
between a large population-based cohort study and the
nationwide cancer registry. Although the ﬂow method may
outperform the independent case ascertainment by having
the advantage of measuring completeness during the registra-
tion process,5 it does not appropriately describe the data
when cancer registration begins with a delay, and is therefore
not used in the NCR. Data on cancer diagnoses was collected
independently, partly from different sources and with differ-
ent aims, that is, determining statistics on cancer incidence,
prevalence and survival by the NCR while investigating
aetiology by the RS. Although these aims are different, opti-
mal cancer registration is fundamental for both purposes.
However, it should be noted that the current study is con-
ducted within persons aged ≥45 years and that these ﬁndings
may differ among a younger population. Furthermore, we
cannot rule out that cancers without pathological conﬁrma-
tion are actually benign. However, we classiﬁed cancers based
on all available medical information, thereby limiting the
number of false-positive diagnoses.
Based on our ﬁndings, we have identiﬁed the main limita-
tions of both registries, which opens avenues for improve-
ments. Date of diagnosis was misclassiﬁed in 11.8% in the
RS. Since this information is not always documented in the
medical ﬁles, we can improve the accuracy by standardised
linkage with the NCR. Regarding the NCR, it is of the utmost
importance to investigate the reason why some pathology-
conﬁrmed cancers are not captured. Therefore, continuous
improvement of registration quality is necessary, especially
regarding cancers in elderly and at speciﬁc cancer sites such
as pancreas, lung and haematological cancers. In addition,
many nonpathology-conﬁrmed cancers were not registered by
the NCR. Cancer diagnoses in the NCR are primarily notiﬁed
by the pathology laboratories and the national hospital dis-
charge registry. However, outpatients are included in the
national hospital discharge registry as of 2015, which is
expected to improve notiﬁcation of nonpathology-conﬁrmed
cancers to the NCR. This effect is mainly visible in lung can-
cer, for which the proportion of nonpathology-conﬁrmed can-
cers increased from 8% in 1989–2012 (the inclusion period of
our study) to 13% in 2015–2017. Since this misclassiﬁcation
could result in an underestimation of cancer incidence, inclu-
sion of these clinically diagnosed cancers may provide more
accurate cancer statistics. However, cancers diagnosed by gen-
eral practitioners or nursing home physicians without further
diagnostics that include pathology or referral to a hospital are
still not be captured by the NCR.
In conclusion, our ﬁndings indicate that linkage of differ-
ent cancer registries is needed to improve registration by iden-
tifying the reasons of inaccurate cancer registration. Cancer
registration by national cancer registries may complement
cancer registration by population-based cohort studies and
vice versa. Combination of different sources is needed to pro-
vide reliable data on cancer incidence.
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